Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression

Clinical Immunology

Volumn 123, Issue 3, 2007, Pages 298-310

  Huang, Jianhua ^a   Wang, Yao ^a   Guo, Jia ^a   Lu, Haiyan ^a   Lin, Xingshi ^a   Ma, Lin ^a   Teitz Tennenbaum, Seagal ^b   Chang, Alfred E ^b   Li, Qiao ^a,b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apoptosis; Bcl gene family members; Cytokines; Dendritic cells; Radiotherapy

Indexed keywords

CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 4; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; GENE EXPRESSION; IMMUNOGLOBULIN PRODUCTION; KIDNEY CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIGENS, CD; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BONE MARROW CELLS; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOKINES; DENDRITIC CELLS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; NECROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOTHERAPY; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249326159     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.02.005     Document Type: Article

References (56)

1. Cao X., Zhang W., Wang J., et al. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 97 (1999) 616-625
2. Lou Y., Wang G., Lizee G., Kim G., et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 64 (2004) 6783-6790
3. Shimzu K., Fields R., Griedlin M., et al. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2268-2273
4. Tatsumi T., Takehara T., Kanto T., et al. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res. 61 (2001) 7563-7567
5. Yang S., Hillinger S., Riedl K., et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumorresponses and confers tumor immunity. Clin. Cancer Res. 10 (2004) 2891-2901
6. Ghosh M., Pal C., Ray M., et al. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J. Immunol. 170 (2003) 5625-5629
7. Jeffes E., Zhang J., Hoa N., et al. Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma. J. Immunol. 174 (2005) 2533-2543
8. Tong Y., Song W., and Crystal R. Combined intratumoral injection of bone marroe-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 61 (2001) 7530-7535
9. Ito F., Li Q., Shreiner A., et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64 (2004) 8411-8419
10. Gong J., Nikrui N., Chen D., et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165 (2000) 1705-1711
11. Labarriere N., Bretaudeau L., Gervois N., et al. Apoptopic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int. J. Cancer 101 (2002) 280-286
12. Boczkowski D., Nair S., Snyder D., et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184 (1996) 465-472
13. Wolfers J., Lozier A., Raposo G., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7 (2001) 297-303
14. Mayordama J., Zorina T., Storkus W., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1 (1995) 1-6
15. Strome S., Voss S., Wilcox R., et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 62 (2002) 1884-1889
16. Friedman E. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des. 8 (2002) 1765-1780
17. Teitz-Tennenbaum S., Li Q., Rynkiewicz S., et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res. 63 (2003) 8466-8475
18. - responder T cells than C57BL/6 mice. J. Leukoc. Biol. 78 (2005) 114-121
19. Wood M., Udagawa T., Hida Y., et al. X-linked dominant growth suppression of transplanted tumors in C57Bl/6J-scid mice. Cancer Res. 65 (2005) 5690-5695
20. Munder A., Zelmer A., Schmiedl A., et al. Murine pulmonary infection with Listeria monocytogenes: differential susceptibility of BALB/c, C57BL/6 and DBA/2 mice. Microbes Infect. 7 (2005) 600-611
21. Pereira V., Lorena V., Nakazawa M., et al. Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection. Parasitol. Res. 96 (2005) 154-161
22. Melgar S., Karlsson A., and Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol.: Gasterointest. Liver Physiol. 288 (2005) G1328-G1338
23. Kimura A., Ishida Y., Wada T., et al. MRP-1 expression levels determine strain-specific susceptibility to sodium arsenic-induced renal injury between C57BL/6 and BALB/c mice. Toxicol. Appl. Pharmacol. 203 (2005) 53-61
24. Walsh N., Bravo-Nuevo A., Geller S., et al. Resistance of photoreceptors in the C57BL/6-c2J, C57BL/6J, and BALB/cJ mouse strains to oxygen stress: evidence of an oxygen phenotype. Curr. Eye Res. 29 (2004) 441-447
25. Scott M., Hoth J., Gardner S., et al. Genetic background influences natural killer cell activation during bacterial peritonitis in mice, and is interleukin 12 and interleukin 18 independent. Cytokine 28 (2004) 124-136
26. Stenstrom M., Skold M., Andersson A., et al. Natural killer T-cell populations in C57BL/6 and NK1.1 congenic BALB.NK mice - a novel thymic subset defined in BALB. NK mice. Immunology 114 (2005) 336-345
27. Takada I., Noguchi Y., Kenjo A., et al. Analysis of CD8 T-cell response by IFN-gamma ELISPOT and H2L(d)/pRL1a tetramer assays in PRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c × C57BL/6) F (1) mice. Cancer Sci. 95 (2004) 254-259
28. Jonathan E., Bernhard E., and McKenna W. How does radiation kill cells?. Curr. Opin. Chem. Biol. 3 (1999) 77-83
29. Albert M., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
30. Rayala S.K., Mascarenhas J., Vadlamudi R.K., and Kumar R. Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis. Mol. Cancer Ther. 5 (2006) 230-237
31. Liu R., Bal H.S., Desta T., Behl Y., and Graves D.T. Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am. J. Pathol. 168 (2006) 757-764
32. Aruga A., Aruga E., Tanigawa K., et al. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159 (1997) 664-673
33. Hu H., Urba W., and Fox B. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 161 (1998) 3033-3041
34. Ito T., Carr A., Svensson H., et al. Antitumor reactivity of Anti-CD3/Anti-CD28 bead-activated lymphoid cells: Implications for cell therapy in a murine model. J. Immunother. 26 (2003) 222-233
35. Li Q., Carr A., Ito F., et al. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res. 63 (2003) 2546-2552
36. Li Q., Grover A., Donald E., et al. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. J. Immunol. 175 (2005) 1424-1432
37. Lugade A., Moran J., Gerber S., et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174 (2005) 7516-7523
38. Cheng E.H., Wei M.C., Weiler S., et al. Bcl-2, Bcl-xL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8 (2001) 705-711
39. Yamamoto K., Morishita S., Hayashi H., et al. Contribution of Bcl-2, but not Bcl-xL and Bax, to anti-apoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension 37 (2001) 1341-1348
40. Reagan-Shaw S., Breur J., and Ahmad N. Enhancement of UVB radiation-mediated apoptosis by sanguinarine in HaCaT human immortalized keratinocytes. Mol. Cancer Ther. 5 (2006) 418-429
41. Mantena S.K., Sharma S.D., and Katiyar S.K. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol. Cancer Ther. 5 (2006) 296-308
42. Chang W.K., Yang K.D., Chuang H., Jan J.T., and Shaio M.F. Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels. Clin. Immunol. 104 (2002) 151-160
43. Charo J., Finkelstein S.E., Grewal N., Restifo N.P., Robbins P.F., and Rosenberg S.A. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 65 (2005) 2001-2008
44. Hurtado J.C., Kim Y.J., and Kwon B.S. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158 (1997) 2600-2609
45. Kuwana T., Mackey M.R., and Perkins G. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111 (2002) 331-342
46. Santiago M.F., Perez-Reyes P.L., Lopez-Aparicio P., Recio M.N., and Perez-Albarsanz M.A. Differential effects of PCBs on the induction of apoptosis machinery and PKCalpha translocation in rat renal tubular cell cultures. Toxicol. Lett. 163 (2006) 91-100
47. Sedlak T.W., Oltvai Z.N., Yang E., et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7834-7838
48. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., and Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell 80 (1995) 285-291
49. Candido K., Shimizu K., McLaughlin J., et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res. 61 (2001) 228-236
50. Tanaka F., Yamaguchi H., Ohta M., et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effects in vivo. Int. J. Cancer 101 (2002) 265-269
51. Li Q., Carr A., Donald E., et al. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res. 65 (2005) 1063-1070
52. Foote L., Evans J., Cifuni J., et al. Interleukin-4 produces a breakdown of tolerance in vivo with autoantibody formation and tissue damage. Autoimmunity 37 (2004) 569-577
53. Schmid S., Molteni A., Fuchtenbusch M., et al. Reduced IL-4 associated antibody responses to vaccine in early pre-diabetes. Diabetologia 45 (2002) 677-685
54. Sudowe S., Arps V., and Kolsch E. The role of interleukin-4 in the regulation of sequential isotype switch from immunoglobin G1 to immunoglobin E antibody protection. Scand. J. Immunol. 51 (2000) 461-471
55. Nikitina E., and Gabrilovich D. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int. J. Cancer. 94 (2001) 825-833
56. Chang A., Redman B., Whitfield J., et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8 (2002) 1021-1032